Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVOR-TIMI 53: Saxagliptin CV Outcomes in T2D
NCT01107886Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- May 2010
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin with Placebo (2 arms). Primary endpoint: Composite of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Ischaemic Stroke at 2.9 years. Started May 2010; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01107886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01107886.